Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE4
Clinical Trials Related to Rigel Pharmaceuticals
Related studies linked through entity extraction aliases.
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
- Status
- RECRUITING
- Phase
- PHASE4
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
- Status
- WITHDRAWN
- Phase
- PHASE2
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
- Status
- RECRUITING
- Phase
- PHASE2
Study of Olutasidenib and Temozolomide in HGG
- Status
- RECRUITING
- Phase
- PHASE2